BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Gane, Edward J. ^{[3
]}

Agarwal, Kosh ^{[4
]}

Wong, Grace Lai-Hung C. ^{[5
]}

Lim, Young-Suk ^{[6
]}

Chen, Chi-Yi ^{[7
]}

Lim, Seng Gee ^{[8
]}

Yatsuhashi, Hiroshi ^{[9
]}

Fung, Scott K. ^{[10
]}

Abramov, Frida ^{[11
]}

Wang, Hongyuan ^{[11
]}

Yee, Leland J. ^{[11
]}

Flaherty, John F. ^{[11
]}

Pan, Calvin Q. ^{[12
]}

Marcellin, Patrick ^{[13
]}

机构：

[1] Hosp Univ Vall Dhebron, Barcelona, Spain

[2] Ciberehd Inst Carlos III, Madrid, Spain

[3] Univ Auckland, Auckland, New Zealand

[4] Kings Coll Hosp London, Inst Liver Studies, London, England

[5] Chinese Univ Hong Kong, MDAC, Hong Kong, Peoples R China

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[7] Chiayi Christian Hosp, Chiayi, Taiwan

[8] Natl Univ Hlth Syst, Singapore, Singapore

[9] Natl Hosp Org Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Gilead Sci Inc, Foster City, CA 94404 USA

[12] NYU, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[13] Univ Paris, Hop Beaujon, AP HP, Paris, France

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1405C

引用

页码：S507 / S509

页数：3

共 50 条

[1] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik-Yuen
Buti, Maria
Flisiak, Robert
Ryder, Stephen
Streinu-Cercel, Adrian
Flaherty, John F.
Gaggar, Anuj
Mo, Shuyuan
Subramanian, G. Mani
Zoulim, Fabrian
Andreone, Pietro
Marcellin, Patrick
GUT, 2018, 67 : A97 - A97
[2] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
Buti, Maria
Stepanova, Tatjana
Celen, Mustafa K.
Flisiak, Robert
Ryder, Stephen D.
Streinu-Cercel, Adrian
Gurel, Selim
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Mo, Shuyuan
Subramanian, Mani
Nurmukhametova, Elena
Zoulim, Fabien
Andreone, Pietro
Marcellin, Patrick
HEPATOLOGY, 2017, 66 : 488A - 488A
[3] FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT
Gane, Edward J.
Buti, Maria
Fung, Scott K.
Chan, Henry Lik Yuen
Izumi, Namiki
Chuang, Wan Long
Ahn, Sang Hoon
Mehta, Rajiv M.
Gurel, Selim
Abramov, Frida
Yee, Leland J.
Wang, Hongyuan
Mateo, Roberto
Flaherty, John F.
Ma, Xiaoli
Pan, Calvin Q.
Lim, Young-Suk
Marcellin, Patrick
HEPATOLOGY, 2023, 78 : S519 - S520
[4] SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE
Buti, Maria
Lampertico, Pietro
Lim, Young-Suk
Agarwal, Kosh
Fung, Scott K.
Tsang, Owen
Elkhashab, Magdy
Kao, Jia-Horng
Luis Calleja, Jose
Khalili, Mandana
Ravendhran, Natarajan
Tan, Susanna
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Wu, George
Hann, Hie-Won L.
Pan, Calvin
Kim, Hyung Joon
Kennedy, Patrick T. F.
Chan, Henry Lik Yuen
HEPATOLOGY, 2019, 70 : 301A - 301A
[5] BONE AND RENAL SAFETY ARE IMPROVED IN CHRONIC HBV PATIENTS 1 YEAR AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik Yuen
Seto, Wai Kay
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
GUT, 2019, 68 : A141 - A142
[6] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
Seto, Wai Kay Walter
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey H.
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott K.
Chuang, Wan-Long
Gane, Edward J.
HEPATOLOGY, 2018, 68 : 240A - 241A
[7] Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF)
Hamzah, L.
Jones, R.
Bailey, A.
Williams, D.
Johnson, M.
Ibrahim, F.
Musso, C.
Burling, K.
Campbell, L.
Post, F.
HIV MEDICINE, 2019, 20 : 8 - 9
[8] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
Pan, Calvin Q.
Gane, Edward
Seto, Wai-Kay
Janssen, Harry L.
Caruntu, Florin
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Bae, Ho
Mo, Shuyuan
Suri, Vithika
Gaggar, Anuj
Flaherty, John F.
Kao, Jia-Horng
Brunetto, Maurizia Rossana
Buti, Maria
GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
[9] Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Janssen, Harry
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Fehmi, Tabak
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chaudhuri, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E457 - E458
[10] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF)
Ahn, Sang Hoon
Kao, Jia-Horng
Hann, Hie-Won
Scott, Fung
Trinh, Huy
Nguyen, Tuan Trong
Paik, Seung Woon
Gaggar, Anuj
Flaherty, John
Yee, Leland
Jump, Belinda
Sethi, Shalini
Wu, George
Chan, Carol Yee Kwan
GUT, 2020, 69 : A73 - A74

← 1 2 3 4 5 →